MA34174B1 - Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a - Google Patents
Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1aInfo
- Publication number
- MA34174B1 MA34174B1 MA35328A MA35328A MA34174B1 MA 34174 B1 MA34174 B1 MA 34174B1 MA 35328 A MA35328 A MA 35328A MA 35328 A MA35328 A MA 35328A MA 34174 B1 MA34174 B1 MA 34174B1
- Authority
- MA
- Morocco
- Prior art keywords
- tetraazabenzo
- azulenes
- vasopressin
- receptors
- cyclohexyl
- Prior art date
Links
- 102000000908 Vasopressin V1A receptors Human genes 0.000 title 1
- 108050007942 Vasopressin V1A receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001545 azulenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical class C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000001568 sexual effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA PRÉSENTE INVENTION PORTE SUR DES HÉTÉROARYL-CYCLOHEXYL-TÉTRAAZABENZO[E]AZULÈNES DE FORMULE (I) DANS LAQUELLE R1, R2 ET R 3 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION. LES COMPOSÉS SELON L'INVENTION SERVENT DE MODULATEURS DES RÉCEPTEURS V1A ET EN PARTICULIER D'ANTAGONISTES DES RÉCEPTEURS V1A. L'INVENTION PORTE ÉGALEMENT SUR LEUR FABRICATION, SUR DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET SUR LEUR UTILISATION COMME MÉDICAMENTS. LES COMPOSÉS ACTIFS DE LA PRÉSENTE INVENTION SONT UTILES COMME AGENTS THÉRAPEUTIQUES AGISSANT DE MANIÈRE PÉRIPHÉRIQUE ET CENTRALE DANS LES AFFECTIONS DE DYSMÉNORRHÉE, DE DISFONCTIONNEMENT SEXUEL MASCULIN OU FÉMININ, D'HYPERTENSION, D'INSUFFISANCE CARDIAQUE CHRONIQUE, DE SÉCRÉTION INAPPROPRIÉE DE VASOPRESSINE, DE CIRRHOSE DU FOIE, DE SYNDROME NÉPHROTIQUE, D'ANXIÉTÉ, DE TROUBLES OBSESSIONNELS-COMPULSIFS, DE TROUBLES DU SPECTRE AUTISTIQUE, DE SCHIZOPHRÉNIE ET DE COMPORTEMENT AGRESSIF.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10160643 | 2010-04-21 | ||
| PCT/EP2011/056071 WO2011131596A1 (fr) | 2010-04-21 | 2011-04-18 | Hétéroaryl-cyclohexyl-tétraazabenzo[e]azulènes comme antagonistes des récepteurs de la vasopressine v1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA34174B1 true MA34174B1 (fr) | 2013-04-03 |
Family
ID=43919925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA35328A MA34174B1 (fr) | 2010-04-21 | 2011-04-18 | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8492376B2 (fr) |
| EP (1) | EP2560975B1 (fr) |
| JP (1) | JP5579923B2 (fr) |
| KR (1) | KR101506776B1 (fr) |
| CN (1) | CN102858776B (fr) |
| AR (1) | AR080927A1 (fr) |
| AU (1) | AU2011244407B2 (fr) |
| BR (1) | BR112012026890A2 (fr) |
| CA (1) | CA2795526A1 (fr) |
| CL (1) | CL2012002905A1 (fr) |
| CO (1) | CO6640209A2 (fr) |
| CR (1) | CR20120513A (fr) |
| CY (1) | CY1116661T1 (fr) |
| DK (1) | DK2560975T3 (fr) |
| EA (1) | EA021418B1 (fr) |
| EC (1) | ECSP12012210A (fr) |
| ES (1) | ES2542953T3 (fr) |
| HR (1) | HRP20150929T1 (fr) |
| HU (1) | HUE026538T2 (fr) |
| IL (1) | IL222403A (fr) |
| MA (1) | MA34174B1 (fr) |
| MX (1) | MX2012012046A (fr) |
| MY (1) | MY160457A (fr) |
| NZ (1) | NZ602627A (fr) |
| PE (2) | PE20130190A1 (fr) |
| PH (1) | PH12012502066A1 (fr) |
| PL (1) | PL2560975T3 (fr) |
| PT (1) | PT2560975E (fr) |
| RS (1) | RS54121B1 (fr) |
| SG (1) | SG184534A1 (fr) |
| SI (1) | SI2560975T1 (fr) |
| TW (1) | TWI419890B (fr) |
| UA (1) | UA109543C2 (fr) |
| WO (1) | WO2011131596A1 (fr) |
| ZA (1) | ZA201207689B (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2356123T1 (sl) * | 2008-11-13 | 2013-01-31 | F. Hoffmann-La Roche Ag | Piro-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo(e)azuleni |
| KR101385433B1 (ko) * | 2008-11-18 | 2014-04-14 | 에프. 호프만-라 로슈 아게 | 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터 |
| HRP20131067T1 (hr) * | 2008-11-28 | 2013-12-06 | F. Hoffmann - La Roche Ag | Arilcikloheksileteri od dihidrotetraazabenzoazulena za primjenu kao antagonista receptora vazopresina v1a |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
| NZ720340A (en) | 2013-12-05 | 2020-03-27 | Hoffmann La Roche | Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crystalline forms thereof |
| WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
| KR102704497B1 (ko) | 2017-12-08 | 2024-09-10 | 에프. 호프만-라 로슈 아게 | 약학 제형 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) * | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| EP3894414B1 (fr) | 2018-12-12 | 2024-04-10 | Neumora Therapeutics, Inc. | Dérivés de 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazépine en tant qu'antagonistes de vasopressin pour le traitement de maladies neuro-psychologiques |
| JP7688692B2 (ja) * | 2020-07-23 | 2025-06-04 | エフ． ホフマン－ラ ロシュ アーゲー | バソプレシン受容体ｖ１ａアンタゴニストとしてのヘテロアリール－メチル置換トリアゾール |
| EP4185570B1 (fr) * | 2020-07-23 | 2024-10-09 | F. Hoffmann-La Roche AG | Triazoles substitués par cyclohexyle utilisés en tant qu'antagonistes du récepteur v1 de la vasopressine |
| CN114644635B (zh) * | 2020-12-21 | 2023-02-03 | 上海济煜医药科技有限公司 | 三氮唑类三并环衍生物及其制备方法和应用 |
| CN116836111A (zh) * | 2023-09-01 | 2023-10-03 | 峰成医药科技(天津)有限公司 | 一种氟代吡啶的连续化合成方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0655673B2 (ja) * | 1988-04-27 | 1994-07-27 | シェリング・コーポレーション | Ｐａｆ拮抗薬‐抗ヒスタミン剤の組合せ及び使用方法 |
| US5185331A (en) * | 1991-05-14 | 1993-02-09 | Merck & Co., Inc. | Triazolobenzodiazepines |
| EP0638560A4 (fr) * | 1991-10-11 | 1995-03-29 | Yoshitomi Pharmaceutical | Medicament utilise pour traiter l'osteoporose et compose de diazepine. |
| US5516774A (en) * | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| AU772397B2 (en) | 1999-01-19 | 2004-04-29 | Ortho-Mcneil Pharmaceutical, Inc. | Tricyclic benzodiazepines as vasopressin receptor antagonists |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| AP2005003376A0 (en) * | 2003-02-19 | 2005-09-30 | Pfizer | Triazole compounds useful in therapy. |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| UA84208C2 (en) | 2004-05-25 | 2008-09-25 | Пфайзер Продактс Инк. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| GB0412874D0 (en) * | 2004-06-09 | 2004-07-14 | Pfizer Ltd | Novel pharmaceuticals |
| EP1632494A1 (fr) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Antagonistes de la v1a vasopressine |
| WO2006021882A1 (fr) | 2004-08-25 | 2006-03-02 | Pfizer Limited | Triazolobenzodiazepines et leur utilisation en tant qu'antagonistes de la vasopressine |
| US7221269B2 (en) * | 2004-10-29 | 2007-05-22 | Kimberly-Clark Worldwide, Inc. | Self-adjusting portals with movable data tag readers for improved reading of data tags |
| EP1877399A1 (fr) | 2005-04-26 | 2008-01-16 | Pfizer Limited | Derives de triazole utilises comme antagonistes de la vasopressine |
| CA2608718A1 (fr) | 2005-05-18 | 2006-11-23 | Pfizer Limited | Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine |
| BRPI0806538A2 (pt) | 2007-01-12 | 2014-04-22 | Hoffmann La Roche | Derivados de glicinamida de espiropiperidina |
| EA018612B1 (ru) * | 2008-01-24 | 2013-09-30 | Панацеа Биотек Лимитед | Новые гетероциклические соединения |
| KR101385433B1 (ko) | 2008-11-18 | 2014-04-14 | 에프. 호프만-라 로슈 아게 | 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터 |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2011
- 2011-04-14 US US13/086,422 patent/US8492376B2/en not_active Expired - Fee Related
- 2011-04-18 DK DK11714564.9T patent/DK2560975T3/en active
- 2011-04-18 RS RS20150473A patent/RS54121B1/sr unknown
- 2011-04-18 EA EA201291092A patent/EA021418B1/ru not_active IP Right Cessation
- 2011-04-18 PL PL11714564T patent/PL2560975T3/pl unknown
- 2011-04-18 PH PH1/2012/502066A patent/PH12012502066A1/en unknown
- 2011-04-18 PT PT117145649T patent/PT2560975E/pt unknown
- 2011-04-18 MA MA35328A patent/MA34174B1/fr unknown
- 2011-04-18 WO PCT/EP2011/056071 patent/WO2011131596A1/fr not_active Ceased
- 2011-04-18 CN CN201180019877.XA patent/CN102858776B/zh not_active Expired - Fee Related
- 2011-04-18 ES ES11714564.9T patent/ES2542953T3/es active Active
- 2011-04-18 MY MYPI2012004627A patent/MY160457A/en unknown
- 2011-04-18 KR KR1020127030366A patent/KR101506776B1/ko not_active Expired - Fee Related
- 2011-04-18 EP EP11714564.9A patent/EP2560975B1/fr not_active Not-in-force
- 2011-04-18 JP JP2013505426A patent/JP5579923B2/ja not_active Expired - Fee Related
- 2011-04-18 CA CA2795526A patent/CA2795526A1/fr not_active Abandoned
- 2011-04-18 NZ NZ602627A patent/NZ602627A/xx not_active IP Right Cessation
- 2011-04-18 BR BR112012026890A patent/BR112012026890A2/pt not_active IP Right Cessation
- 2011-04-18 MX MX2012012046A patent/MX2012012046A/es active IP Right Grant
- 2011-04-18 SG SG2012075156A patent/SG184534A1/en unknown
- 2011-04-18 UA UAA201213290A patent/UA109543C2/uk unknown
- 2011-04-18 AU AU2011244407A patent/AU2011244407B2/en not_active Ceased
- 2011-04-18 HR HRP20150929TT patent/HRP20150929T1/hr unknown
- 2011-04-18 PE PE2012002055A patent/PE20130190A1/es not_active Application Discontinuation
- 2011-04-18 PE PE2016000352A patent/PE20160589A1/es not_active Application Discontinuation
- 2011-04-18 SI SI201130543T patent/SI2560975T1/sl unknown
- 2011-04-18 HU HUE11714564A patent/HUE026538T2/en unknown
- 2011-04-18 TW TW100113411A patent/TWI419890B/zh not_active IP Right Cessation
- 2011-04-19 AR ARP110101333A patent/AR080927A1/es unknown
-
2012
- 2012-09-24 CO CO12165814A patent/CO6640209A2/es not_active Application Discontinuation
- 2012-10-02 EC ECSP12012210 patent/ECSP12012210A/es unknown
- 2012-10-10 CR CR20120513A patent/CR20120513A/es unknown
- 2012-10-11 IL IL222403A patent/IL222403A/en active IP Right Grant
- 2012-10-12 ZA ZA2012/07689A patent/ZA201207689B/en unknown
- 2012-10-18 CL CL2012002905A patent/CL2012002905A1/es unknown
-
2015
- 2015-08-27 CY CY20151100757T patent/CY1116661T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA34174B1 (fr) | Hetéroaryl-cyclohexyl-tétraazabenzo[e)azulènes comme antagonistes des récepteurs de la vasopressine v1a | |
| MA34173B1 (fr) | Hhétérobiaryl-cyclohexyl-tétraazabenzo[e]azulènes | |
| MA34252B1 (fr) | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes | |
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| ATE541572T1 (de) | Tetrahydro-naphtalinderviate als glucocorticoidrezeptor-modulatoren | |
| MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
| TN2009000324A1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides | |
| WO2008080844A9 (fr) | Dérivés azaspiro | |
| ATE423769T1 (de) | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| MA30289B1 (fr) | Dérivés d'amines | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA34147B1 (fr) | Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales | |
| MA30778B1 (fr) | Derives de sulfonamides servant d'agonistes adrenergique et d'antagonistes muscariniques | |
| MX2009007411A (es) | Derivados de espiropiperidina-glicinamida. | |
| MA32627B1 (fr) | Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase | |
| TNSN08137A1 (fr) | Derives de carboxamides servant d'antagonistes des recepteurs muscariniques | |
| MY147588A (en) | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MA35893B1 (fr) | Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7 | |
| MA32506B1 (fr) | Nouveaux composes | |
| MX2009005507A (es) | Derivados de espiro-piperidina. |